

# The formation of carbamazepine metabolites and carbamazepine-protein conjugates in epilepsy patients

<b>Submission date</b> 18/02/2015	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 19/02/2015	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 21/09/2021	<b>Condition category</b> Nervous System Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Carbamazepine is an effective drug that is used in the treatment of epilepsy, neuralgia and psychiatric disorders. Although generally well tolerated, it can cause hypersensitivity reactions such as a skin rash in up to 10% of patients. These reactions can result in hospital admission, long-term complications such as blindness, and can cause death in up to 30% of patients. These reactions are caused by the immune system. Recent research has identified that patients with specific genes are at a higher risk of developing this hypersensitivity. Carbamazepine is converted by the liver to other chemical products called metabolites. It is believed that one or more of these metabolites activate the immune system. However, it is not known how this happens. This aim of this study is to assess the stable and toxic products formed in the blood and urine of patients receiving carbamazepine.

### Who can participate?

Adults aged at least 18 who have either just been prescribed carbamazepine or have received the treatment at the same dose for at least 4 weeks

### What does the study involve?

Participants provide blood and urine samples in order to identify the chemicals responsible for triggering the immune system in susceptible people. Genetic variations are also analysed to determine their effects on carbamazepine.

### What are the possible benefits and risks of participating?

These results may help to explain the variation in carbamazepine hypersensitivity between patients. Lessons learned from this research will provide valuable information for other drugs that cause similar hypersensitivity reactions (e.g. penicillins). Improved understanding of the mechanism of carbamazepine hypersensitivity will enable safer drug design in future and the development of predictive tests that can diagnose and identify patients susceptible to adverse reactions.

Where is the study run from?  
University of Liverpool (UK)

When is the study starting and how long is it expected to run for?  
November 2013 to April 2015

Who is funding the study?  
Medical Research Council (UK)

Who is the main contact?  
Dr Vincent Yip

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Vincent Yip

**Contact details**  
University of Liverpool  
Wolfson Centre for Personalised Medicine  
Department of Pharmacology  
Block A: Waterhouse Buildings  
1-5 Brownlow Street  
Liverpool  
United Kingdom  
L69 3GL

## Additional identifiers

**Clinical Trials Information System (CTIS)**  
2013-002743-28

**Protocol serial number**  
15543

## Study information

**Scientific Title**  
A pharmacokinetic investigation into the formation of carbamazepine metabolites and carbamazepine-protein conjugates in epilepsy patients

**Acronym**  
PICME II

**Study objectives**

This study aims to improve our mechanistic understanding of carbamazepine hypersensitivity by using high sensitivity mass spectrometry to characterise and quantify the stable and toxic products formed in the blood and urine of patients receiving carbamazepine therapy.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

13/NW/0503

### **Study design**

Non-randomised; Both; Treatment

### **Primary study design**

Interventional

### **Study type(s)**

Treatment

### **Health condition(s) or problem(s) studied**

Topic: Neurological; Subtopic: Neurological (all Subtopics); Disease: Epilepsy

### **Interventions**

Patients in the auto-induction group will be newly prescribed carbamazepine. All other subjects in the study will have been prescribed carbamazepine by their neurologist as part of clinical care for patient for at least 4 weeks.

### **Intervention Type**

Drug

### **Phase**

Not Applicable

### **Drug/device/biological/vaccine name(s)**

Carbamazepine

### **Primary outcome(s)**

Pharmacokinetic analyses; Timepoint(s): Time points dependent on time of presentation to clinic

### **Key secondary outcome(s)**

N/A

### **Completion date**

30/04/2015

## **Eligibility**

### **Key inclusion criteria**

**Autoinduction group:**

1. Subject is willing and able to give written informed consent
2. Subject is aged 18 or over
3. Subject is newly prescribed carbamazepine by their attending physician

**Maintenance group:**

1. Subject is willing and able to give written informed consent
2. Subject is aged 18 or over
3. Subject has received CBZ therapy at the same dosage for at least 4 weeks

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria****Autoinduction group:**

1. Subject is not willing to take part or unable to give written informed consent
2. Subject has in the past 4 weeks received other medication that is a CYP3A4 inducer or inhibitor (see medications below)
3. Subject has taken part on another research study within 90 days of commencement
4. Subject has any condition which in the opinion of the investigator will interfere with the study

**Excluded medications:**

Rifampicin, Amiodarone, Fluvoxamine, Saquinavir, Rifampin, Amprenavir, Indinavir, SVerapamil, Isoniazid, Atazanavir, Lopinavir, Verapamil, Phenytoin, Azithromycin, Mifepristone, Phenobarbital, Grapefruit juice, Nelfinavir, Omeprazole, Clarithromycin, Norverapamil, Clotrimazole, Cyclosporine A, Ritonavir, HMGCoA reductase inhibitors, Delavirdine, Ndesmethylerythromycin, Cyclophosphamide, Erythromycin, Roxithromycin, Spironolactone, Fluoxetine, RVerapamil

**Maintenance group:**

1. Subject is not willing to take part or unable to give written informed consent
2. Subject has any condition which in the opinion of the investigator will interfere with the study

**Date of first enrolment**

05/11/2013

**Date of final enrolment**

30/04/2015

# Locations

## Countries of recruitment

United Kingdom

England

## Study participating centre

### University of Liverpool

Wolfson Centre for Personalised Medicine

Department of Pharmacology

Block A: Waterhouse Buildings

1–5 Brownlow Street

Liverpool

United Kingdom

L69 3GL

# Sponsor information

## Organisation

University of Liverpool

## ROR

<https://ror.org/04xs57h96>

# Funder(s)

## Funder type

Government

## Funder Name

Medical Research Council

## Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, Medical Research Committee and Advisory Council, MRC

## Funding Body Type

Government organisation

## Funding Body Subtype

National government

## Location

United Kingdom

# Results and Publications

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>		01/06/2021	21/09/2021	Yes	No
<a href="#">HRA research summary</a>			28/06/2023	No	No